Immix Biopharma (US:IMMX) — Company Overview, News & Financial Data
Immix Biopharma develops innovative oncology treatments to meet unmet medical needs, focusing on clinical advancements in immunotherapy.
Immix Biopharma
Immix Biopharma (NASDAQ:IMMX) is a biotech firm focused on developing and bringing innovative treatments to patients with unmet medical needs, particularly in the oncology and immunotherapy spaces. The company is actively working on several pioneering projects aimed at tackling some of the most challenging diseases by advancing their proprietary platforms and drug candidates through clinical trials. Their objective is to significantly improve patient outcomes by harnessing the power of cutting-edge science and targeted therapies. Through strategic partnerships and rigorous research and development efforts, Immix Biopharma strives to emerge as a key player in transforming the landscape of modern medicine and healthcare.
Snapshot
Operations
Products and/or services of Immix Biopharma
- Imx-110: First-in-class therapeutic for solid tumors, utilizing a novel approach to target cancer.
- Nanoparticle albumin-bound (nab) technology: Enhances delivery of chemotherapy drugs to improve cancer treatment effectiveness.
- Imx-120: Innovative project focused on developing treatments for rare and difficult-to-treat cancers.
- Collaborations with academic institutions: Partnerships to accelerate drug discovery and development processes.
Immix Biopharma executive team
- Dr. Ilya Rachman M.B.A., M.D., Ph.D.Co-Founder, CEO & Chairman
- Mr. Gabriel Morris B.A.CFO & Director
- Dr. Graham Ross FFPM, M.D.Chief Medical Officer & Head of Clinical Development
- Mr. Sean Senn J.D., M.B.A., M.Sc.Co-Founder
- Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.Scientific Co-Founder
- Dr. David Marks MBBS, Ph.D.Chief Medical Officer of Cell Therapy
- Mr. Mel Davis-PickettHead of CMC Technical Development
- Mr. Michael A. GrabowChief Commercial Officer